Razuvaev Anton, Henderson Bimma, Girnita Leonard, Larsson Olle, Axelson Magnus, Hedin Ulf, Roy Joy
Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, SE-17176 Stockholm, Sweden.
J Vasc Surg. 2007 Jul;46(1):108-15. doi: 10.1016/j.jvs.2007.02.066.
Smooth muscle cell proliferation (SMC) is a pivotal factor in the development of intimal hyperplasia after vascular injury. A number of growth factors, including insulin-like growth factor-1 (IGF-1), have been shown to be involved in SMC proliferation. We evaluated the effect of picropodophyllin (PPP), a new IGF-1 receptor inhibitor, in the prevention of SMC proliferation and development of intimal hyperplasia after vascular injury.
The effects of systemic administration of PPP on intimal hyperplasia were studied in a balloon rat carotid injury model. Lesions were quantified by morphometry and SMC proliferation and apoptosis was studied by immunohistochemical staining for proliferating cell nuclear antigen (PCNA) and activated caspase 3, respectively. The effect of PPP on rat aortic SMC proliferation and apoptosis was studied in vitro by using cell counting, 3[H]-thymidine incorporation, and a flow cytometry assay for annexin V. Phosphorylation of the IGF-1 receptor, protein kinase B (Akt), and extracellular signal-regulated kinase 1/2 (ERK1/2) in vitro and in vivo were analyzed by using Western blotting.
PPP inhibited IGF-1-mediated SMC proliferation in vitro but no significant increase in apoptosis was detected. In rats treated with PPP, a more than a twofold reduction in carotid intima area was observed 2 weeks after balloon injury, a significant decrease in PCNA staining was demonstrated in early lesions, but activated caspase 3 was not detected. In addition, PPP attenuated phosphorylation of the IGF-1 receptor, Akt, and ERK1/2 in IGF-1-stimulated SMCs in vitro, and a reduced phosphorylation of the IGF-1 receptor and Akt was found in balloon-injured carotid arteries in rats treated with PPP.
These results show that PPP potently blocks IGF-1-mediated phosphorylation of the IGF-1 receptor in SMCs, decreases downstream Akt and ERK1/2 activation, inhibits SMC replication, and subsequently attenuates intimal hyperplasia after balloon injury of rat carotid arteries.
平滑肌细胞增殖(SMC)是血管损伤后内膜增生发展的关键因素。包括胰岛素样生长因子-1(IGF-1)在内的多种生长因子已被证明与SMC增殖有关。我们评估了新型IGF-1受体抑制剂鬼臼苦素(PPP)在预防血管损伤后SMC增殖和内膜增生发展中的作用。
在大鼠颈动脉球囊损伤模型中研究全身给予PPP对内膜增生的影响。通过形态计量学对病变进行量化,并分别通过增殖细胞核抗原(PCNA)免疫组化染色和活化的半胱天冬酶3研究SMC增殖和凋亡。通过细胞计数、3[H]-胸腺嘧啶核苷掺入以及膜联蛋白V流式细胞术检测在体外研究PPP对大鼠主动脉SMC增殖和凋亡的影响。通过蛋白质印迹分析体外和体内IGF-1受体、蛋白激酶B(Akt)和细胞外信号调节激酶1/2(ERK1/2)的磷酸化。
PPP在体外抑制IGF-1介导的SMC增殖,但未检测到凋亡显著增加。在用PPP治疗的大鼠中,球囊损伤后2周观察到颈动脉内膜面积减少了两倍多,早期病变中PCNA染色显著降低,但未检测到活化的半胱天冬酶3。此外,PPP在体外减弱了IGF-1刺激的SMC中IGF-1受体、Akt和ERK1/2的磷酸化,在用PPP治疗的大鼠的球囊损伤颈动脉中发现IGF-1受体和Akt的磷酸化降低。
这些结果表明,PPP有效阻断SMC中IGF-1介导的IGF-1受体磷酸化,降低下游Akt和ERK1/2活化,抑制SMC复制,随后减轻大鼠颈动脉球囊损伤后的内膜增生。